ArticleGlobal public health2017
Japan Tobacco International: To 'be the most successful and respected tobacco company in the world'.
Article in Global public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Recent Trends in Cigarette and HTP Use in Japan: A Scoping Review.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Article
- Smoking attitudes, self-reported practices, and COPD knowledge among adults aged 20-59 years: Insights from a Japanese sample.Tobacco induced diseases · 2025Article
- 'They have a right to participate as a stakeholder': Article 5.3 implementation and government interactions with the tobacco industry in Ethiopia.Tobacco control · 2022Article
- Tobacco control in Nepal during a time of government turmoil (1960-2006).Tobacco control · 2020Article
- Looming threat of Asian tobacco companies to global health.Lancet (London, England) · 2017Article
- The globalisation strategies of five Asian tobacco companies: An analytical framework.Global public health · 2017Article
- The Taiwan Tobacco and Liquor Corporation: To 'join the ranks of global companies'.Global public health · 2017Article
- The globalisation strategies of five Asian tobacco companies: a comparative analysis and implications for global health governance.Global public health · 2017Article
- Smoking history and emphysema in asthma-COPD overlap.International journal of chronic obstructive pulmonary disease · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Japan Tobacco International (JTI) is the international division of Japan Tobacco Incorporated, and the world's third largest transnational tobacco company. Founded in 1999, JTI's rapid growth has been the result of a global business strategy that potentially serves as a model for other Asian tobacco companies. This paper analyses Japan Tobacco Incorporated's global expansion since the 1980s in response to market opening, foreign competition, and declining share of a contracting domestic market. Key features of its global strategy include the on-going central role and investment by the Japanese government, and an expansion agenda based on mergers and acquisitions. The paper also discusses the challenges this global business strategy poses for global tobacco control and public health. This paper is part of the special issue 'The Emergence of Asian Tobacco Companies: Implications for Global Health Governance'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.